Sen. Rand Paul’s Expedited Access to Biosimilars Act was unanimously advanced by the Senate HELP Committee last week, opening a path for the FDA to approve biosimilars without full clinical trials if analytical testing shows comparable metabolism. For clinicians, the practical upside is earlier access to lower-cost biologics: former FDA Commissioner Martin Makary said the change could cut development costs by up to $150 million and bring products to patients 2 to 4 years sooner.

The Move

• Paul’s bill would permanently codify prior FDA guidance allowing biosimilar approval based on analytical and pharmacologic evidence rather than requiring redundant full-scale clinical trials.

• The measure applies to biosimilars — highly similar versions of already approved biologics, including antibodies used in allergy, arthritis and cancer care, plus drugs in categories like GLP-1 agonists and VEGF inhibitors.

• The Senate Health, Education, Labor, and Pensions Committee voted the bill out unanimously, giving the proposal bipartisan procedural momentum.

Why it Matters for Care

• Lower development burdens could accelerate clinician access to cheaper alternatives for commonly used biologics in oncology, rheumatology, endocrinology and ophthalmology.

• Biosimilars already tend to launch at roughly 15% to 35% below brand-name prices, and their entry often pressures originator manufacturers to cut prices too.

• At the bedside, that can translate into fewer access delays, less payer friction and better treatment continuity for patients facing cost barriers.

Between the Lines

• The bill reflects a deregulatory argument: if a biosimilar has already demonstrated close analytical similarity and comparable metabolism, mandatory efficacy trials may add cost and time without changing approval outcomes.

• Supporters are framing this as a competition policy as much as a drug-policy change, aimed at weakening brand biologic market advantages.

• For health systems and payers, faster biosimilar uptake could modestly ease spending pressure in some of the most expensive drug classes.

What to Watch

• Whether Senate leadership brings the bill to the floor and whether the House takes up a companion measure.

• How the FDA would operationalize the law if enacted, including what analytical and pharmacokinetic thresholds would suffice in place of full trials.

• Whether manufacturer, patient or specialty society groups push back over extrapolation, interchangeability or confidence in narrower preapproval evidence packages.

Source: Reason